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In 1988, the World Health Assembly launched the 
Global Polio Eradication Initiative, which aimed to use large-
scale vaccination with the oral vaccine to eradicate polio 
worldwide by the year 2000. Although important progress 
has been made, polio remains endemic in several countries. 
Also, the current control measures will likely be inadequate 
to deal with problems that may arise in the postpolio era. 
A panel convoked by the National Research Council con-
cluded that the use of antiviral drugs may be essential in the 
polio eradication strategy. We here report on a compara-
tive study of the antipoliovirus activity of a selection of mol-
ecules that have previously been reported to be inhibitors 
of picornavirus replication and discuss their potential use, 
alone or in combination, for the treatment or prophylaxis of 
poliovirus infection.
T
he Global Polio Eradication Initiative (GPEI) was 
launched by the World Health Assembly more than 
18 years ago. The principal idea behind the GPEI was to 
eliminate polio worldwide by the year 2000 by means of 
large-scale vaccination with the oral live attenuated polio 
vaccine (OPV) developed by Albert Sabin (1). The GPEI 
has resulted, since 1988, in a decrease in poliomyelitis 
cases from 350,000 to <2,000 (2,3). Today, poliovirus 
(PV) is endemic in 4 countries (Nigeria, India, Pakistan, 
and Afghanistan), whereas the virus was prevalent in >125 
countries at the time the initiative was launched (4). When 
wild PV transmission has been interrupted, the World 
Health Organization proposes ending the global routine 
OPV to prevent the risk for vaccine-associated paralytic 
poliomyelitis, chronic infection of immunodeﬁ  cient per-
sons, and the reestablishment of poliomyelitis through 
circulating vaccine-derived PV (5). A panel was convened 
by the National Research Council to evaluate the poten-
tial for an antiviral drug as one of the tools to minimize 
poliomyelitis risk after OPV cessation. The conclusion of 
the panel was that it would be appropriate, and possibly 
essential, to develop antiviral drugs for PV infection, as 
an additional tool to address the problems that might arise 
in the “postpolio” era (6). Antiviral agents do not confer 
immunity but could be used prophylactically as well as 
therapeutically. They could protect inactivated polio vac-
cine (IPV) recipients from PV infection, limit spread until 
immunity can be ensured and help clear vaccine-derived 
PV from persistently infected persons (7). The ideal drug 
would be safe, inexpensive, easy to use, stable, and mani-
fest broad activity toward PV strains.
To date, few, if any, drug discovery programs for PV 
have been initiated. Therefore, research initiatives leading 
to the successful development of anti-PV drugs will have 
to rely on the current knowledge of existing picornavirus 
antiviral agents. Antipicornavirus compounds that reached 
clinical trials are scarce, and despite the fact that some 
of these drugs have demonstrated activity against certain 
picornavirus-associated conditions in humans, no speciﬁ  c 
antipicornavirus agent has yet been approved by the US 
Food and Drug Administration (FDA) (8).
A substantial number of small molecule compounds 
have been reported as potent inhibitors of the replication of 
picornaviruses in vitro (8). These compounds could serve 
as scaffolds for the development of more potent and selec-
tive inhibitors of PV. The information available on their 
structure-activity relationship and their mechanism of ac-
tion could be exploited as a solid base for developing a spe-
ciﬁ  c anti-PV therapy.
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We report on a comparative study of a selected series 
of antipicornavirus drugs for their ability to inhibit PV rep-
lication in vitro. The unique aspect of this report lies in the 
fact that 1) certain drugs (e.g., rupintrivir) were speciﬁ  cally 
developed to treat rhinovirus and other infections and have 
never been evaluated for their ability to block PV replica-
tion and 2) the selected compounds have never been com-
pared in parallel by using the same technique against the 3 
vaccine strains.
Rationale for Selection of Antipicornavirus Drugs
Because this study was triggered by the recognition 
that antiviral drugs will be needed in the postvaccination 
era as a countermeasure against the persistence or reemer-
gence in the environment of vaccine-associated virus, we 
decided to conﬁ  ne our study to the 3 Sabin strains used 
for vaccination. The aim was to include compounds that 
act on different targets in the picornavirus replication cycle 
(preferably 1 or 2 compounds per target) (Figure 1). When 
a rather large number of molecules had been described 
that act through the same target (e.g., for the capsid bind-
ing agents), we selected those compounds that were in the 
most advanced state of development and preferably had 
been studied in a clinical setting. When only 1 or a few 
compounds had been described for a particular target (for 
example, with enviroxime, the sole protein 3A–targeting 
drug reported so far), the impact in the clinical setting was 
considered less important. Ribavirin was included as a ref-
erence standard, since it was regarded as a broad-spectrum 
inhibitor of positive-strand RNA viruses.
Methods
The antiviral and cytotoxic activities of the se-
lected compounds were initially determined by means 
of a cell protection assay. In this assay, a soluble tetra-
zolium compound (3-[4,5-dimethylthiazol-2-yl]-5-[3-
carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazoli-
um [MTS]), when used in combination with an electron 
transfer reagent (phenazine methosulfate [PMS]) is biore-
duced by viable cells in culture, a reaction that is colori-
metrically quantiﬁ  ed. The antiviral and cytotoxic activi-
ties were expressed as mean effective concentration (EC50, 
the compound concentration that inhibits virus-induced 
cytopathic effect [CPE] formation by 50%) and 50% cy-
totoxic concentration (CC50). Therapeutic indexes (TIs) 
were expressed as the ratio between the CC50 and the EC50. 
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Figure 1. Structural formulas of selected poliovirus inhibitors. A) Capscid binders; 
B) protease inhibitors; C) 3A inhibitor; D) nucleoside analogs; E) 2C inhibitors; F) 
unknown target. HBB, 2-(α-hydroxybenzyl)-benzimidazole.Antiviral Agents against Poliovirus
Brieﬂ  y, HeLa cells (ATCC CCL-2), grown to conﬂ  uency 
in 96-well plates, were infected with 100 50% cell culture 
infectious doses of virus. After an adsorption period of 2 
hours at 37°C, unadsorbed virus was removed and serial 
dilutions of the compounds were added. The cultures were 
further incubated at 37°C for 3 days, until complete CPE 
was observed in the infected and untreated virus control. 
For cytotoxicity determination, uninfected cultures were 
incubated with dilution series of compound for 3 days at 
37°C. After removal of the medium, 90 μL medium and 
10 μL MTS/PMS (Promega, Leiden, the Netherlands) were 
added to each well; after an incubation period of 2 hours 
at 37°C, the optical density of each well was read at 498 
nm in a microplate reader. EC50 values were calculated as 
previously described (9). 
Results
Capsid-binding Agents
One of the best studied targets for antiviral therapy 
in picornaviruses is a hydrophobic pocket underneath the 
canyon ﬂ  oor that surrounds each 5-fold axis of the viral 
capsid. Binding of speciﬁ  c inhibitors into this pocket in-
creases virion rigidity, thus inhibiting attachment or dis-
assembly of the viral particle after receptor binding (10). 
Consequently, the release of the viral genome into the host 
cell is prevented and viral replication is inhibited. Two of 
the most extensively characterized series of capsid-bind-
ing agents are the so-called WIN compounds, developed 
by Sterling Winthrop (New York, NY, USA), and a series 
of pyridazine analogs developed by the Janssen Research 
Foundation (Beerse, Belgium). The prototypes of these se-
ries are pleconaril (11) and pirodavir (12), respectively.
In clinical studies, pleconaril was a promising candi-
date for treating the common cold, but it was disapproved 
by the FDA in 2002, mainly because of possible interac-
tions with other drugs, including those for birth control. 
Soon thereafter, pleconaril was licensed to Schering-
Plough, which in 2007 completed a phase II clinical trial 
to study the effects of pleconaril nasal spray on common 
cold symptoms and asthma exacerbations following human 
rhinovirus (HRV) exposure. Meanwhile, pleconaril is still 
being used successfully on a compassionate basis for treat-
ing life-threatening enterovirus infections in children (13). 
Notably, it was effective in stopping virus excretion in a 
child persistently infected with PV, when combined with 
gamma globulin–mediated virus clearance (14). In another 
trial with a persistently infected person, however, treatment 
produced no beneﬁ  t (7).
Intranasal pirodavir (R77975) was active in some 
clinical trials of human experimental rhinovirus infections, 
but lack of therapeutic efﬁ  cacy and metabolic instability 
after oral administration halted further development. As 
shown in the Table, pleconaril and pirodavir, as well as 
a pirodavir analog (R78206) (15) inhibited PV2 and PV3 
replication with EC50 values <2 μmol/L and TIs of 60 to 
>178. However, only R78206 exhibited inhibitory activity 
against PV1. Pirodavir proved 5- to 20-fold less active on 
PV1 replication, and pleconaril was inactive up to the high-
est concentration tested.
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Table. Inhibitory activity of selected compounds against replication of poliovirus Sabin strains 1, 2, and 3 in HeLa cells, as determined 
by a CPE reduction assay* 
EC50 (μmol/L) 
Compound  PV1 PV2  PV3 
Toxicity 
(CC50;μmol/L) TI  (min–max) 
Capsid binders           
  Pirodavir analog (R78206)  0.76 ± 0.18  0.22 ± 0.19  0.11 ± 0.10  27 ± 34  35–245 
  Pleconaril  >100  1.1 ± 0.6  0.22 ± 0.15  66 ± 6  <0.66–300 
  Pirodavir (R77975)  10 ± 1  1.7 ± 0.1  0.56 ± 0.03  >100  >10–>179 
Protease inhibitors           
  Rupintrivir  0.022 ± 0.028  0.041 ± 0.024  0.0052 ± 0.0046  >100  >2,439–>19,231 
  Compound 1  0.26 ± 0.24  0.31 ± 0 .21  0.060 ± 0 .000  >100  >322–>1,667 
3A inhibitor           
  Enviroxime  0.2 ± 0.25  0.056 ± 0.020  0.035 ± 0.029  58 ± 6  290–1,657 
Nucleoside analogs           
  Ribavirin  57 ± 13  64 ± 4  55 ± 7  >100  >1.6–>1.8 
 2'-C-methylcytidine†  15 ± 18  29 ± 27  3.9 ± 2.3  >100  >3.5–>26 
 2'-C-methyladenosine  5.5 ± 0.0  5.6 ± 0.1  5.4 ± 0.4  84 ± 0  15 
 4’-azidocytidine  >100  >100  >100  >100  ><1 
2C inhibitors           
  HBB  300 ± 68  225 ± 128  295 ± 88  >400  >1.3–>1.8 
  MRL-1237  5.3 ± 0.3  4.6 ± 1.4  3.8 ± 2.5  >100  >19–>26 
Unknown target           
  MDL-860  6.0 ± 1.6  3.6 ± 2.2  2.2 ± 1.5  >100  >17–>45 
*CPE, cytopathic effect; EC50, 50% effective concentration; CC50, 50% cytotoxic concentration; PV, poliovirus; TI, therapeutic index (CC50/EC50); min, 
minimum; max, maximum; HBB, 2-(Į-hydroxybenzyl)-benzimidazole.  
†Valopicitabine (oral valine ester prodrug of 2ƍ-C-methylcytidine).  SYNOPSIS
Protease Inhibitors
A second approach to inhibiting PV replication is by 
targeting the virus-encoded proteases 2A and/or 3C. These 
enzymes cleave the single polyprotein, encoded by the PV 
genome, into mature proteins. Rupintrivir (AG-7088, Pﬁ  z-
er, New York, NY, USA) is an irreversible inhibitor of the 
3C function (16,17). Despite some successful trials in pa-
tients that were experimentally infected with HRV, rupin-
trivir was not able to mitigate disease severity in studies of 
natural rhinovirus infection, and clinical development was 
stopped (18). Further efforts by Pﬁ  zer resulted in the devel-
opment of compound 1, an inhibitor with a similar mecha-
nism of action and with an excellent oral bioavailability 
(18). Both compounds inhibited all 3 PV strains with EC50s 
<1 μmol/L and TIs of >384 to >19,230 (Table). Rupintrivir 
was the most potent compound of the selected series with 
EC50 values in the nanomolar range (5–40 nmol/L) against 
each of the 3 tested PV strains (Table).
Protein 3A Inhibitors
Enviroxime is a benzimidazole derivative that inhibits 
the replication of enteroviruses and rhinoviruses in vitro by 
targeting the nonstructural protein 3A (19,20). Enviroxime 
inhibited the replication of all 3 strains of PV, with EC50 
values of 35–200 nmol/L and TIs of 290–1,657 (Table). 
Previous in vivo studies with enviroxime, however, have 
shown toxicity and only weak to moderate activity, due to 
poor solubility and pharmacokinetics (21–24). Structural 
derivatives of enviroxime such as the C2- and vinylacety-
lene analogs were reported to have a better oral bioavailabil-
ity and pharmacologic proﬁ  le (25,26) and may therefore be 
considered as leading candidates for further development.
Nucleoside Analogs
The nucleoside analog ribavirin is an antiviral drug 
with broad-spectrum activity against RNA and DNA vi-
ruses. Ribavirin is used in combination with interferon in 
the treatment of hepatitis C virus (HCV) infection (27) 
and as an aerosol to treat respiratory syncytial virus infec-
tions in children (28). As expected, ribavirin proved to be a 
weak inhibitor of PV replication with EC50 values of 50–60 
μmol/L (TIs >1.8). Valopicitabine is the oral valine ester 
prodrug of another nucleoside analog, 2′-C-methylcytidine. 
The 5′-triphosphate of 2′-C-methylcytidine is an inhibitor 
of HCV polymerase (29). Clinical development of valop-
icitabine for the treatment of HCV infection was recently 
stopped, mainly because of gastrointestinal side effects. 
The compound was shown to exhibit relatively broad-spec-
trum activity against positive-sense single-stranded RNA 
viruses, including inhibition of the replication of foot-
and-mouth-disease virus (30). It can be assumed that the 
mechanism by which 2′-C-methylcytidine inhibits picor-
naviruses is also by inhibition of the viral polymerase. As 
shown in the Table, 2′-C-methylcytidine inhibited the rep-
lication of PV strains with EC50 values of 3.9–29 μmol/L 
(TIs >3.4–>25.6). The adenosine analog of valopicitabine, 
as well as another nucleoside analog, 4′-azidocytidine (a 
potent inhibitor of HCV replication) were also included in 
this study. 2′-C-methyladenosine proved equipotent (≈5 
μmol/L) against all 3 PV strains; whereas 4′-azidocytidine 
proved inactive (Table).
Protein 2C Inhibitors
MRL-1237 and 2-(α-hydroxybenzyl)-benzimidazole 
(HBB) are inhibitors that target the enteroviral nonstruc-
tural protein 2C (31,32). MRL-1237 showed antiviral ac-
tivity against PV strains 1, 2, and 3 with TIs >19. HBB ap-
peared to be a weak inhibitor of PV replication with EC50s 
of 200–300 μmol/L and TIs >1.3.
Compounds with Unknown Mechanism of Action
Compound MDL-860 was discovered as a broad-
spectrum inhibitor of picornavirus replication, although 
the precise mechanism of antiviral activity has never been 
unraveled (33). The anti-PV activity of MDL-860 proved 
comparable to that of the 2C inhibitor MRL-1237.
To further conﬁ  rm the activity observed in the CPE re-
duction assays, infectious virus yield reduction assays were 
carried out on the supernatant of PV1-infected cultures. As 
depicted in Figure 2, rupintrivir, the most active compound 
in the CPE reduction assay, caused a 6-log10 decrease of 
infectious virus production at 100 μmol/L, and reduced 
virus progeny formation 10–1,000-fold at concentrations 
of 10–100 nmol/L. Conversely, pleconaril, which did not 
protect against PV1-induced CPE formation, was not able 
to reduce infectious virus yield. A similar correlation be-
tween CPE formation and infectious virus production was 
observed for all other compounds include in the study (data 
not shown).
Discussion and Perspectives
From our comparative study, rupintrivir and its analog 
compound 1 emerged as highly potent and broad-spectrum 
anti-PV compounds, without any signs of cytotoxicity up 
to the highest concentrations tested. The in vitro activity of 
these protease inhibitors against PV is comparable to their 
activity against various strains of HRV, the virus against 
which the compounds were originally developed (17,35). 
Given the excellent oral bioavailability (35) and its favor-
able pharmacokinetic proﬁ  le, compound 1 may be an at-
tractive candidate for further study for the treatment and 
prophylaxis of PV infection.
The pirodavir analog R78206 also displayed potent, 
broad-spectrum activity against PV. As was the case with 
rupintrivir, pirodavir did not appear to offer sufﬁ  cient 
potential for treating HRV infection and was not further 
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developed. The compound, however, was well tolerated; 
thus, pirodavir (and its analogs) may, alone or combined 
with other antiviral agents, open perspectives for treat-
ing PV infection. One major problem with pirodavir and 
its analog, however, is the poor pharmacokinetic proﬁ  le 
after systemic dosing due to hydrolysis of the ester bond. 
Orally bioavailable analogs of pirodavir were developed 
at Biota (Melbourne, Victoria, Australia) but appeared to 
have a limited activity toward PV strains (36). Another 
compound that has undergone extensive clinical evalua-
tion for enteroviral infections is pleconaril. The compound 
is relatively potent in inhibiting PV2 and PV3 replication, 
but has no activity against PV1, which limits its potential 
for PV. Besides pleconaril and pirodavir (analog), several 
other potent capsid-binding agents have been reported 
(reviewed in [8]).
Enviroxime, discovered in 1980, which exhibits potent 
anti-PV activity, was not developed because of unfavor-
able pharmacokinetics. However, a further exploration of 
the potential of enviroxime analogs could be worthwhile, in 
an attempt to improve the activity, selectivity, and in par-
ticular, the pharmacokinetic proﬁ  le (25,26).
Compounds that have been less well characterized 
but that still may form a starting point for the synthesis 
of more potent and selective inhibitors of PV replication 
are MRL-1237 and MDL-860. Unraveling the precise 
mode of antiviral activity and the molecular interaction 
with their antiviral target may allow structure-based drug 
design.
Nucleoside polymerase inhibitors that have been de-
veloped for treating HCV infection may also have the po-
tential to inhibit other single-stranded positive-sense RNA 
viruses. Here we demonstrate that the active component 
of the anti-HCV drug valopicitabine inhibits the replica-
tion of all 3 PV strains. If such a drug becomes available 
for treating HCV infections, it could also be used “off-
label” to treat PV infection. However, 4′-azidocytidine, 
a potent inhibitor of HCV replication (37), was devoid of 
anti-PV activity up to the highest concentrations tested. 
As reported before and conﬁ  rmed here, ribavirin proved 
to be a relatively weak inhibitor of PV replication (TIs 
>1.8). Although ribavirin has limited activity against 
HCV when used as monotherapy, its potency is markedly 
increased when it is given in combination with pegylated 
interferon. Since extensive clinical experience exists re-
garding the use of ribavirin in treating HCV infection, it 
may be possible and beneﬁ  cial to explore the potential of 
the combined use of ribavirin with drugs such as rupintri-
vir, pirodavir, or their analogs.
Because of the high mutation rate of the viral RNA-
dependent RNA polymerase, drug-resistant PV mutants 
have been readily selected in cell culture (32,38). The pos-
sibility that the use of antiviral drugs to treat polio would 
result in the appearance of drug-resistant variants cannot 
therefore be excluded. It should be noted, however, that the 
most potent inhibitors of in vitro PV replication that we 
identiﬁ  ed here (the 3C inhibitors rupintrivir and compound 
1, the capsid binders R78206 and pleconaril, and the 3A 
inhibitor enviroxime), act on different targets in the viral 
replication cycle. The use in combination of drugs with 
different modes of action will likely delay or prevent the 
emergence of drug-resistant variants. Moreover, the period 
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Figure 2. Effect of selected inhibitors on production of infectious poliovirus 1 Sabin in HeLa cell cultures. Supernatants collected from 3 
independent experiments were titrated for infectious virus content, and 50% cell culture infective dose (CCID50) values were calculated as 
described by Reed and Muench (34). A) Ruprintrivir; B) enviroxime; C) MRL-1237; D) pleconaril.SYNOPSIS
of treatment during an acute PV outbreak would likely be 
much shorter than treatment regimens for such chronic in-
fections as HIV or HCV, reducing the chance that drug-
resistant strains will emerge.
As highlighted earlier, the need for adequate antiviral 
drugs against PV (most likely in combination with IPV) in 
the ﬁ  nal stages of polio eradication is obvious. In a recent 
report from the World Health Organization (39), an advi-
sory committee concurred with the proposal to establish a 
“PV antiviral initiative,” to take forward the key recom-
mendations proposed during the National Research Coun-
cil meeting on antiviral agents against PV.
In the present study, several drugs, some of which have 
been (rupintrivir, pirodavir, valopicitabine, compound 1) or 
are being (pleconaril) studied in the clinical setting, are re-
ported to inhibit the in vitro replication of PVs to varying 
degrees. These drugs, used alone or in combination, may 
have potential for the treatment or prophylaxis of PV infec-
tions. These and other compounds may serve as starting 
points for the design of more potent PV inhibitors with fa-
vorable safety and pharmacokinetic proﬁ  les.
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